Search

Your search keyword '"Jenette Creaney"' showing total 213 results

Search Constraints

Start Over You searched for: Author "Jenette Creaney" Remove constraint Author: "Jenette Creaney"
213 results on '"Jenette Creaney"'

Search Results

1. Comprehensive genomic and tumour immune profiling reveals potential therapeutic targets in malignant pleural mesothelioma

2. What’s next in cancer immunotherapy? - The promise and challenges of neoantigen vaccination

3. Immune marker expression of irradiated mesothelioma cell lines

4. How Our Continuing Studies of the Pre-clinical Inbred Mouse Models of Mesothelioma Have Influenced the Development of New Therapies

6. Tumour associated lymphocytes in the pleural effusions of patients with mesothelioma express high levels of inhibitory receptors

7. Neutrophil-to-lymphocyte ratio in malignant pleural fluid: Prognostic significance.

8. Randomised placebo-controlled cross-over study examining the role of anamorelin in mesothelioma (The ANTHEM study): rationale and protocol

9. Pre-treatment tumor neo-antigen responses in draining lymph nodes are infrequent but predict checkpoint blockade therapy outcome

10. Identification of a CD8+ T-cell response to a predicted neoantigen in malignant mesothelioma

11. Whole exome sequencing of an asbestos-induced wild-type murine model of malignant mesothelioma

12. Calretinin as a blood-based biomarker for mesothelioma

13. The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma

14. Driver Fusions and Their Implications in the Development and Treatment of Human Cancers

15. Spatial Organization and Molecular Correlation of Tumor-Infiltrating Lymphocytes Using Deep Learning on Pathology Images

16. Molecular Characterization and Clinical Relevance of Metabolic Expression Subtypes in Human Cancers

17. Systematic Analysis of Splice-Site-Creating Mutations in Cancer

18. Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas

19. Somatic Mutational Landscape of Splicing Factor Genes and Their Functional Consequences across 33 Cancer Types

20. Machine Learning Detects Pan-cancer Ras Pathway Activation in The Cancer Genome Atlas

21. Pan-Cancer Analysis of lncRNA Regulation Supports Their Targeting of Cancer Genes in Each Tumor Context

22. Integrated Genomic Analysis of the Ubiquitin Pathway across Cancer Types

23. Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas

24. Germline and somatic variant identification using BGISEQ-500 and HiSeq X Ten whole genome sequencing.

25. Association of Biomarker Levels with Severity of Asbestos-Related Diseases

26. Correction: genetic variants associated with increased risk of malignant pleural mesothelioma: a genome-wide association study.

27. Genetic variants associated with increased risk of malignant pleural mesothelioma: a genome-wide association study.

28. Bacterial infection elicits heat shock protein 72 release from pleural mesothelial cells.

29. Auto-antibodies to β-F1-ATPase and vimentin in malignant mesothelioma.

30. BAP1 Loss by Immunohistochemistry Predicts Improved Survival to First-Line Platinum and Pemetrexed Chemotherapy for Patients With Pleural Mesothelioma: A Validation Study

31. Table S6 from Integrative Molecular Characterization of Malignant Pleural Mesothelioma

32. Data from Integrative Molecular Characterization of Malignant Pleural Mesothelioma

33. Supplementary Data from Integrative Molecular Characterization of Malignant Pleural Mesothelioma

34. Supplementary Table 1 from A Molecular Diagnostic Test for Distinguishing Lung Adenocarcinoma from Malignant Mesothelioma Using Cells Collected from Pleural Effusions

35. Data from A Molecular Diagnostic Test for Distinguishing Lung Adenocarcinoma from Malignant Mesothelioma Using Cells Collected from Pleural Effusions

36. Profile of soluble factors in pleural effusions predict prognosis in mesothelioma

37. Diagnostic utility of BAP1 for malignant pleural mesothelioma in pleural fluid specimens with atypical morphology

38. The Current Lung Cancer Neoantigen Landscape and Implications for Therapy

39. Response to 'Revisiting 'BAP1ness' in Malignant Pleural Mesothelioma'

40. A phase II trial of single oral FGF inhibitor, AZD4547, as second or third line therapy in malignant pleural mesothelioma

41. Analysis of early pleural fluid samples in patients with mesothelioma: A case series exploration of morphology, BAP1, and CDKN2A status with implications for the concept of mesothelioma in situ in cytology

42. Characterization of neoantigen-specific T cells in cancer resistant to immune checkpoint therapies

43. Neo-antigen specific T cell responses indicate the presence of metastases before imaging

44. Advances in pathological diagnosis of mesothelioma

45. Malignant Pleural Mesothelioma: an Update for Pulmonologists

46. Simplified Criteria Using Pleural Fluid Cholesterol and Lactate Dehydrogenase to Distinguish between Exudative and Transudative Pleural Effusions

47. Prognostic significance of pleural effusion exhausted CD8+ T cell subsets in non-small cell lung cancer and mesothelioma

48. Immunotherapy strategies for mesothelioma – the role of tumor specific neoantigens in a new era of precision medicine

49. Trace element levels in pleural effusions

50. Increased interdigitation zone visibility on optical coherence tomography following systemic fibroblast growth factor receptor 1-3 tyrosine kinase inhibitor anticancer therapy

Catalog

Books, media, physical & digital resources